The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study - 07/06/21
, Yochai Schonmann, MD, MSc c, Orly Weinstein, MD, MPH c, d, Enno Schmidt, MD, PhD a, Ralf J. Ludwig, MD a, Arnon D. Cohen, MD, PhD c, d
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
The burden of COVID-19 in patients with bullous pemphigoid (BP) and pemphigus is yet to be evaluated.
Objective |
To assess the risks of COVID-19 and COVID-19-associated hospitalization and mortality in patients with BP and pemphigus and to delineate determinants of severe COVID-19 illness among these patients.
Methods |
A population-based cohort study compared COVID-19 and its complications in patients with BP (n = 1845) and pemphigus (n = 1236) with age-, sex-, and ethnicity-matched control subjects.
Results |
The risks of COVID-19 (hazard rate [HR], 1.12; 95% confidence interval [CI], 0.72-1.73; P = .691) and COVID-19-associated hospitalization (HR, 1.58; 95% CI, 0.84-2.98; P = .160) was comparable between patients with BP and controls. The risk of COVID-19-associated mortality was higher among patients with BP (HR, 2.82; 95% CI, 1.15-6.92; P = .023). The risk of COVID-19 (HR, 0.81; 95% CI, 0.44-1.49; P = .496), COVID-19-associated hospitalization (HR, 1.41; 95% CI, 0.53-3.76; P = .499), and COVID-19-associated mortality (HR, 1.33; 95% CI, 0.15-11.92; P = .789) was similar in patients with pemphigus and their controls. Systemic corticosteroids and immunosuppressants did not predispose COVID-19-positive BP and pemphigus patients to a more severe illness.
Limitations |
Retrospective data collection.
Conclusions |
Patients with BP experience increased COVID-19-associated mortality and should be monitored closely. Maintaining systemic corticosteroids and immunosuppressive adjuvant agents during the pandemic is not associated with worse outcomes.
Le texte complet de cet article est disponible en PDF.Key words : bullous pemphigoid, coronavirus disease 2019, COVID-19, hospitalization, mortality, pemphigus
Abbreviations used : AIBD, BP, CHS, CI, HR
Plan
| Funding sources: None. |
|
| IRB approval status: The current study was approved by the Ben-Gurion University IRB in accordance with the declaration of Helsinki (approval code: 0212-17-COM). |
Vol 85 - N° 1
P. 79-87 - juillet 2021 Retour au numéro
Article précédent
- Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis
- Joseph F. Merola, Jerry Bagel, Peter Almgren, Mads A. Røpke, Katja W. Lophaven, Natacha Strange Vest, Parbeer Grewal
- Mucocutaneous manifestations in children hospitalized with COVID-19
- David Andina-Martinez, Montserrat Nieto-Moro, Jose Antonio Alonso-Cadenas, Juan Añon-Hidalgo, Angela Hernandez-Martin, Esther Perez-Suarez, Isabel Colmenero-Blanco, Maria Isabel Iglesias-Bouza, Julia Cano-Fernandez, Ana Mateos-Mayo, Antonio Torrelo
Bienvenue sur EM-consulte, la référence des professionnels de santé.